Clinical Trials Logo

Metastatic Thyroid Cancer clinical trials

View clinical trials related to Metastatic Thyroid Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05668962 Recruiting - Thyroid Cancer Clinical Trials

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Start date: March 1, 2023
Phase: Phase 2
Study type: Interventional

This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer. This research study involves the study drug selpercatinib in combination with standard of care treatments, I-131 and thyrotropin alfa (rhTSH).

NCT ID: NCT04619316 Recruiting - Clinical trials for Metastatic Thyroid Cancer

Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition

ERRITI
Start date: February 5, 2018
Phase: Phase 2
Study type: Interventional

This is a prospective interventional trial that aims to restore iodine incorporation in tumoral lesions of patients with unresectable, radioiodine-refractory thyroid cancer.

NCT ID: NCT03099356 Recruiting - Clinical trials for Metastatic Thyroid Cancer

Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

Start date: April 27, 2017
Phase: Phase 2
Study type: Interventional

This study will be a non-randomized pilot trial using Cyclophosphamide and Sirolimus for the treatment of metastatic differentiated thyroid cancer. Patients will be treated with Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19. Cycle length will be 28 days. Patients will be monitored closely for toxicity and undergo imaging to evaluate efficacy once every 2 cycles.